Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-806-1074
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.49 million
Profitability
Miscellaneous
Employees82
OptionableOptionable
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.05. The biopharmaceutical company earned $1.19 million during the quarter, compared to analyst estimates of $0.94 million. Chimerix had a negative net margin of 1,752.41% and a negative return on equity of 36.40%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
2 equities research analysts have issued 12-month price targets for Chimerix's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Chimerix's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 302.0% from the stock's current price. View Analyst Price Targets for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chimerix.
What are Wall Street analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (1/28/2019)
- 2. HC Wainwright analysts commented, "We base our $10 price target on probability-adjusted revenue forecasts for brincidofovir in AdV, smallpox and multiviral prevention. We use the net present value of our revenue forecast through 2026, apply a 15% POS for brincidofovir in AdV and other viruses, a 35% POS for brincidofovir in smallpox, a 4x price/sales multiple, value the early stage pipeline at $1.56/share and 2Q18 fully diluted net cash of $4.08/share to arrive at our $10 price target. Our P/S multiple of 4x is in line with Chimerix’s peers that range between 2-5x." (9/7/2018)
Has Chimerix been receiving favorable news coverage?
Press coverage about CMRX stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chimerix earned a news impact score of 1.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Rigel Pharmaceuticals (RIGL), OvaScience (OVAS), TG Therapeutics (TGTX), Kezar Life Sciences (KZR), Akebia Therapeutics (AKBA), Lannett (LCI), ArQule (ARQL), ZIOPHARM Oncology (ZIOP), Insys Therapeutics (INSY), Kindred Biosciences (KIN), Sinovac Biotech (SVA), NuCana (NCNA), Stemline Therapeutics (STML), Keryx Biopharmaceuticals (KERX) and Kalvista Pharmaceuticals (KALV).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
- Dr. M. Michelle Berrey, Pres, CEO & Director (Age 52)
- Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
- Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
- Dr. Randall Lanier Ph.D., Chief Science Officer
Who are Chimerix's major shareholders?
Chimerix's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.52%), Dimensional Fund Advisors LP (5.15%), Opaleye Management Inc. (3.98%), New Leaf Venture Partners L.L.C. (2.66%), D. E. Shaw & Co. Inc. (1.30%) and Geode Capital Management LLC (1.27%). Company insiders that own Chimerix stock include Ernest Mario, Linda M Richardson and M Michelle Berrey. View Institutional Ownership Trends for Chimerix.
Which major investors are selling Chimerix stock?
CMRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Rhenman & Partners Asset Management AB, Assenagon Asset Management S.A., Squarepoint Ops LLC, California Public Employees Retirement System and Bank of New York Mellon Corp. View Insider Buying and Selling for Chimerix.
Which major investors are buying Chimerix stock?
CMRX stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., RBF Capital LLC, New Leaf Venture Partners L.L.C., 683 Capital Management LLC, Victory Capital Management Inc., Geode Capital Management LLC, Two Sigma Investments LP and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Chimerix.
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $1.99.
How big of a company is Chimerix?
Chimerix has a market capitalization of $100.94 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.
What is Chimerix's official website?
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
